Oxford Biomedica PLC
21 January 2005
Oxford BioMedica plc (the 'Company')
Notification of Major Interests in Shares
The Company has received notification from Prelude Trust plc that on 19 January
2005, Prelude Trust plc sold 1,500,000 ordinary shares of 1p each in Oxford
BioMedica plc. Prelude Trust plc previously held 19,187,346 shares, and
following this sale, the holding of Prelude Trust plc is 17,687,346 1p ordinary
shares. This represents 4.75% of the presently issued share capital of the
Company, which stands at 372,503,634 shares.
Andrew Wood
Chief Financial Officer
Tel 01865 783000
This information is provided by RNS
The company news service from the London Stock Exchange
*A Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient:
Obtains access to the information in a personal capacity;
Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services;
Is not currently registered or qualified as a professional securities trader or investment adviser with any national or state exchange, regulatory authority, professional association or recognised professional body;
Does not currently act in any capacity as an investment adviser, whether or not they have at some time been qualified to do so;
Uses the information solely in relation to the management of their personal funds and not as a trader to the public or for the investment of corporate funds;
Does not distribute, republish or otherwise provide any information or derived works to any third party in any manner or use or process information or derived works for any commercial purposes.
Please note, this site uses cookies. Some of the cookies are essential for parts of the site to operate and have already been set. You may delete and block all cookies from this site, but if you do, parts of the site may not work. To find out more about the cookies used on Investegate and how you can manage them, see our Privacy and Cookie Policy
To continue using Investegate, please confirm that you are a private investor as well as agreeing to our Privacy and Cookie Policy & Terms.